The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2015: Volume 20/ Issue 23 Article 4
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 20, Issue 23, 11 June 2015
Rapid communications
Zika virus infection in a traveller returning to Europe from Brazil, March 2015
  1. Clinica Malattie Infettive, Dipartimento di Medicina Sperimentale e Clinica, Università Degli Studi di Firenze, Florence, Italy
  2. Bernhard Nocht Institute for Tropical Medicine, WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, National Reference Centre for Tropical Infectious Diseases, Hamburg, Germany
  3. Department of Infectious, Parasitic and Immune-Mediate Diseases, Istituto Superiore di Sanità, Rome, Italy

Citation style for this article: Zammarchi L, Tappe D, Fortuna C, Remoli ME, Günther S, Venturi G, Bartoloni A, Schmidt-Chanasit J. Zika virus infection in a traveller returning to Europe from Brazil, March 2015. Euro Surveill. 2015;20(23):pii=21153. Article DOI:
Date of submission: 05 June 2015

We report a case of laboratory-confirmed Zika virus infection imported into Europe from the Americas. The patient developed fever, rash, and oedema of hands and feet after returning to Italy from Brazil in late March 2015. The case highlights that, together with chikungunya virus and dengue virus, three major arboviruses are now co-circulating in Brazil. These arboviruses represent a burden for the healthcare systems in Brazil and other countries where competent mosquito vectors are present.

Case presentation

A male Italian traveller in his early 60s presented to the Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Careggi, Florence (Italy), four days after his return from a 12-day holiday in Salvador de Bahia, Brazil at the end of March 2015. The patient had a four-day history of confluent slightly-pruritic erythematous rash, diffused on the face, trunk, arms, and legs, accompanied by fever (maximum temperature 38 °C), conjunctivitis, general weakness, and painful oedema of both hands and feet. Blood tests revealed a normal white blood cell count (6,180 cells/µL; reference: 4,000–10,000/µL) with normal differential count, but some activated lymphocytes, thrombocytopenia (112,000/µL; reference: 140,000–440,000/µL) and slightly elevated C-reactive protein (10 mg/L, reference: <9 mg/L). Serum transaminases and creatinine were normal. Because of the clinical presentation and the travel history, a viral infection was suspected, and patient serum was tested for antibodies against chikungunya virus (CHIKV), dengue virus (DENV), Zika virus (ZIKV), Yellow fever virus, West Nile virus, Japanese encephalitis virus, Parvovirus B19, human herpes virus 6 (HHV6), and HIV [1]. The serum sample taken four days after symptom onset showed a positive result for anti-ZIKV-IgM and -IgG antibodies, suggesting an acute or recent ZIKV-infection. Results of the serological tests for the other viruses tested were negative (Table). A follow up sample, taken 26 days after symptoms onset, showed a threefold increase of the anti-ZIKV-IgM and -IgG antibody titres (Table). In addition, a low-titre DENV IgG was now observed (Table), most likely representing a serological cross-reaction of the anti-ZIKV-IgG antibodies (Table). ZIKV-specific real-time reverse transcription-PCR [1] was negative from both samples. Generic flavivirus and alphavirus RT-PCR [1] were also negative. The presence of ZIKV-specific neutralising antibodies in the second serum sample was confirmed by a virus neutralisation assay (Table). The patient was discharged, managed and followed-up in the outpatient department. The patient was recommended symptomatic treatment with paracetamol. The symptoms rapidly resolved in the following week (fever and rash lasted for only four days).

Table. Serological test results and virological data of a case of Zika virus infection imported from Brazil into Italy, March 2015


ZIKV is an arbovirus belonging to the flavivirus genus that was first isolated from a rhesus monkey in the Zika forest in Uganda [2]. It is transmitted by different species of Aedes mosquitoes. Clinical manifestations of ZIKV infection are very similar to those of DENV and CHIKV infections, but usually milder [3]. Human infections have been documented in several African and south-eastern Asian countries [4]. ZIKV was responsible for several outbreaks on islands in the Pacific Ocean, such as Yap Island (Federated States of Micronesia in 2007 [4]) and more recently in French Polynesia, New Caledonia, Easter Island and the Cook Islands in 2013 [5,6]. In several non-endemic countries including Japan, Germany, Italy, Canada, Australia and the United States (US), the infection has been diagnosed in returning travellers [1,7-11].

ZIKV infections have recently been reported in Brazil, where the virus has probably been circulating since 2014 [12]. So far, 16 cases have been confirmed in accordance to the Ministry of Health of Brazil [13].The emergence of ZIKV in Brazil is of concern since Brazil is the country with the highest number of DENV infections world-wide [14]. Moreover, CHIKV has been introduced to South America as well with more than one million of cases diagnosed since 2013 to date [15].

Discussion and conclusions

The ongoing outbreak of now two major mosquito-borne infections in addition to endemic DENV infections has the potential of posing a serious threat to local and supra-national South American healthcare systems, as observed in the Pacific region in recent years [16].

In endemic areas, but also in the setting of travel medicine, ZIKV infection represents both a clinical and diagnostic challenge since the symptoms are very similar to other arboviral diseases, no specific commercial serological tests are available, and cross-reactive DENV serology (IgG or IgM) during ZIKV infection has been described in previously reported cases [11] which may lead to incorrect diagnoses. Recently, neurological complications possibly related to coinfections or sequential infections with dengue virus have been reported in French Polynesia [17].The European Centre for Disease Prevention and Control (ECDC) published a Rapid Risk Assessment on ZIKV in the Americas on 25 May 2015, with the aim of increasing awareness and enhancing vigilance towards the detection of imported cases of ZIKV infection in Europe [18]. This case is, to the best of our knowledge, the first laboratory-confirmed case of a ZIKV infection acquired in the Americas and imported into Europe. The patient had returned to Italy, his home country, where Aedes albopictus, a potential competent vector, is widely distributed. Considering the extensive airline travel between Latin America and other parts of the world where the viruses have not yet been established, but competent vectors are present, such as southern Europe and the southern part of the US, the surveillance systems have to be aware of the appearance of ZIKV in Brazil to avoid further dissemination of the disease. In order to prevent seeding of ZIKV into local mosquito populations, as it happened for CHIKV in Italy in 2007 and in France in 2010 and 2014 [19, 20, 21], screening of febrile returning travellers for arboviral infections, especially in the summer months, is highly advised.

We thank Mathis Petersen (Hamburg), Birgit Huesing (Hamburg), Sabine Koehler (Hamburg), and Eleonora Benedetti (Rome) for excellent technical assistance. We thank Giovanni Rezza (Rome) for revising the manuscript.

Conflict of interest
None declared.

Authors’ contributions
Wrote the manuscript: LZ, DT, JSC, GV; performed laboratory investigations: DT, CF, MER, JSC, GV, SG; revised the manuscript: AB, JSC; managed the patient: LZ.


  1. Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, et al. First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013. Euro Surveill. 2014;19(4):20685. PMID:24507467
  2. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509-20. PMID:12995440
  3. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536-43. PMID:19516034
  4. Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009;15(9):1347-50. PMID:19788800
  5. ProMED-mail. Zika virus - Pacific (06): French Polynesia, New Caledonia. 2014. Archive Number: 20140303.2309965.
  6. ProMED-mail from HealthMap Alerts. ZIKA VIRUS - PACIFIC (09). Promed mail 2014,Archive Number: 20140328.2365267. Available at:
  7. Kutsuna S, Kato Y, Takasaki T, Moi M, Kotaki A, Uemura H, et al. Two cases of Zika fever imported from French Polynesia to Japan, December 2013 to January 2014 [corrected]. Euro Surveill. 2014;19(4):20683. PMID:24507466
  8. ProMED-mail. Zika virus - Canada ex Thailand. Archive Number: 20130529.1744108. Available from:
  9. Kwong JC, Druce JD, Leder K. Zika virus infection acquired during brief travel to Indonesia. Am J Trop Med Hyg. 2013;89(3):516-7. PMID:23878182
  10. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis. 2011;17(5):880-2. PMID:21529401
  11. Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, et al. Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications. J Clin Virol. 2015;63:32-5. PMID:25600600
  12. ProMED-mail. Undiagnosed illness - Brazil (02): Zika virus confirmed. Archive Number: 20150515.3364149 Published Date: 2015-05-15 16:53:35.
  13. Centers for Disease Control and Prevention (CDC). Travelers‘ Health. Zika in Brazil. Atlanta: CDC. [Accessed 10 Jun 2015]. Available from:
  14. World Health Organization. Global strategy for Dengue control and prevention 2012-2020. 2012.
  15. Pan American Health Organization. Number of Reported Cases of Chikungunya Fever in the Americas, by Country or Territory 2013-2014. Updated 15 May 2015.
  16. Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections - an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012-2014. Euro Surveill. 2014;19(41):20929. PMID:25345518
  17. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastère S, Valour F, et al. Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013. Euro Surveill. 2014;19(9):20720. PMID:24626205
  18. European Centre for Disease Prevention and Control (ECDC). Rapid Risk Assessment. Zika virus infection outbreak, Brazil and the Pacific region. 25 May 2015. Stockholm: ECDC. Available from:
  19. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, et al.; CHIKV study group. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840-6. PMID:18061059
  20. Delisle E, Rousseau C, Broche B, Leparc-Goffart I, L Ambert G, Cochet A, et al. Chikungunya outbreak in Montpellier, France, September to October 2014. Euro Surveill. 2015;20(17):21108.
  21. Grandadam M, Caro V, Plumet S, Thiberge JM, Souarès Y, Failloux AB, et al. Chikungunya virus, southeastern France. Emerg Infect Dis. 2011;17(5):910-3. PMID:21529410

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.